Patients were randomly assigned in a @:@:@:@ ratio to receive @ mg simeprevir and @ mg sofosbuvir daily for @ weeks with ( group @ ) or without ( group @ ) ribavirin or for @ weeks with ( group @ ) or without ( group @ ) ribavirin , in two cohorts : previous non-responders with METAVIR scores F@-F@ ( cohort @ ) and previous non-responders and treatment-naive patients with METAVIR scores F@-F@ ( cohort @ ) .